Abstract:Background and purpose:Early evaluating the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) in patients with hepatic cancer is still a diffcult clinical problem. The purpose of this study was to evaluate the ability of the apparent diffusion coeffcient (ADC) to help predict early disease progression after TACE.Methods:Institutional review board approval was obtained, and all patients signed informed consent. Magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) (b=50, 500, 1 000 mm2/s) were performed before and 1 month after initiating TACE for 23 patients with hepatic cancer (14 were male, 9 were female; mean age: 53.3 years;range: 21-85 years). Contrast-enhanced MRI was performed 3 months after initiating TACE. Patients were classiifed as either progressing or non-progressing according to RECIST 1.1. The preoperative ADC values of tumor and the ADC values of tumor 1 month after TACE were analyzed by pairedt-test in both progressing and non-progressing group. Unpairedt-test was used to compare ADC parameters between progressing and non-progressing group. In all the 23 hepatic cancer patients, receiver operating characteristic (ROC) curve analysis was performed to determine a threshold ADC ratio (ADC%) to differentiate progressing from non-progressing patients.Results:Thirteen progressing and 9 non-progressing patients were evaluated. Increase in ADCs of tumor was observed in non-progressing patients at 1 month after TACE compared with preoperative ADCs. There was a signiifcant difference between the 2 groups (P=0.01). In progressing group, preoperative ADCs of tumor were similar to those at 1 month after TACE (P=0.221). There was no significant difference in preoperative ADCs of tumor and ADC% between the progressing and non-progressing groups. In patients with hepatic cancer, 1 month ADC ratio in non-progressing patients were signiifcantly higher than those of progressing patients (P=0.029). Using ROC to evaluate the ability of ADC% could predict early disease pro-gression after TACE. Using -6.455% as the threshold, the area under the ROC curve was 0.867 (95%CI: 0.643-1.000). The sensitivity was 100%, and the speciifcity was 66.7%.Conclusion:One month after TACE, the increases in ADCs of tumor were observed only in the non-progressing group; and the ADC ratio seems to be a promising tool for helping predict the early disease progression after TACE in patients with hepatic cancer.

Study of Animal Experiment and Clinical Application on Evaluating the Curative Effect after Chemoembolization of Liver Tumors by Using of DWI Magnetic Resonance

Assessment of Hepatocellular Carcinoma Undergoing Trans-Catheter Arterial Chemoembolization with Functional Magnetic Resonance Imaging

Application of 3.0T-MRI DWI in evaluating the efficacy of synchronous radiotherapy and chemotherapy for advanced lung cancer

Application of 3.0T magnetic resonance diffusion weighted imaging in the advanced gastric cancer

Diffusion-weighted MR imaging for liver cancer follow-up after transcatheter arterial chemoembolization

Clinical Application of Diffusion Weighted MR Imaging in Follow-Up of Patients Receiving Transcatheter Arterial Chemoembolization for Liver Cancer

Quantitative study in apparent diffusion coefficients evaluate the diffusion-weighted MR imaging for clinical follow-up of liver cancer

[Evaluation of the Effect of Transcatheter Arterial Chemoembolization in Treatment of Primary Hepatocellular Carcinoma with Magnetic Resonance Diffusion-Weighted Imaging: 4-6-week Follow-Up of 25 Cases].

MR diffusion weighted imaging in evaluation on cancer cell repopulation for rabbit models of hepatic VX2 tumor after radiotherapy

The clinical value of MR diffusion-weighted imaging in the follow-up observation of hepatocellular carcinoma after transcatheter arterial chemoembolization

[Water Mobility of Diffusion MRI in Prediction of Response to Chemoembolization in Liver Cancer].

Preliminary Study of MR Diffusion Weighted Imaging in Nude Mice Models of Hepatic Bel7402 Tumors after Adenovirus-Mediated Cytosine Diaminase-Thymidine Kinase Gene Therapy

Role of the Apparent Diffusion Coeffcient of MRI in Evaluating Therapeutic Effcacy after Transcatheter Arterial Chemoembolization in Hepatic Cancer Patients

Dynamic Contrast-Enhanced And Diffusion-Weighted Magnetic Resonance Imaging Noninvasive Evaluation Of Vascular Disrupting Treatment On Rabbit Liver Tumors

Diffusion-weighted Imaging and Variable Flip Angle T1 Mapping: a Supplement for Image-Guided Biopsy in Follow-Up Analysis of Liver Fibrosis

Value of MR Diffusion Weighted Imaging in Evaluating Therapeutic Effect of Fluorouracil in Rats Transplanted by Hepatocellular Carcinoma Subcutaneously

Utility of diffusion-weighted imaging to assess hepatocellular carcinoma viability following transarterial chemoembolization.

Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma.

An Experimental Research on Various ADC Value on Different Areas of Liver Tumor

The value of MR diffusion-weighted imaging in the assessment of tumor response after TACE ;in patients with hepatocellular carcinoma

Intravoxel incoherent motion diffusion-weighted imaging and shear wave elastography for evaluating peritumoral liver fibrosis after transarterial chemoembolization in a VX2 rabbit liver tumor model